These abstracts from the ASCO 2018 annual meeting caught our attention for their potential impact on clinical practice and research in the field.
Preliminary data from the first prospective clinical trial shows higher blood-based tumor burden works as biomarker for effective atezoli-zumab treatment in non-small cell lung cancer patients.
Results from this first set of patients demonstrate that strong biological signals are present in unscreened cancers that are typically diagnosed at late stages, and that signals correlate highly across assays.
Starting immunotherapy first-line for patients with melanoma containing BRAF mutations, followed by BRAF + MEK inhibitors, was associated with longer survival and lower costs compared with prescribing inhibitors first.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
IMmotion151 compared therapy with atezolizumab, a monoclonal anti-body of IgG1 isotype against PD-L1, and bevacizumab, an anti-VEGF monoclonal antibody approved to treat many cancer types, with sunitinib.
A phase 2 trial demonstrates promising results in patients with glioblastoma who take SurVaxM, an immunotherapy vaccine that targets survivin.
People with a higher incidence of cancer — multiple melanomas, melanoma and additional cancers or a family history of melanomas and other malignancies — can carry a higher risk for breast, pros-tate, brain and other cancers.
Results of a multi-institutional phase 1b clinical trial show women with metastatic HER2+ breast cancer respond well to the combina-tion of trastuzumab emtansine and neratinib.
Cleveland Clinic researchers are part of a new effort to generate prospective clinical genomics that inform treatment decisions in patients with glioblastoma
Please join our staff as we participate or present in the following oral and poster presentations at the 2018 ASCO Annual Meeting